(1S,3R,7S,8S,8aR)-8-((3R,5R)-3,5-dihydroxy-7-(hydroxyamino)-7-oxoheptyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (S)-2-methylbutanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (1S,3R,7S,8S,8aR)-8-((3R,5R)-3,5-dihydroxy-7-(hydroxyamino)-7-oxoheptyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (S)-2-methylbutanoate
• 英文别名: Me2C10H10(OC(O)CH(Me)Et)CH2CH2CH(OH)CH2CH(OH)CH2C(O)NHO；[(1S,3R,7S,8S,8aR)-8-[(3R,5R)-3,5-dihydroxy-7-(hydroxyamino)-7-oxoheptyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate
• 化学式: C₂₄H₃₉NO₆
• 分子量: 437.577
• InChiKey: UZLJJCAWULBGEN-BXMDZJJMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  31
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  116
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (1S,3R,7S,8S,8aR)-8-((3R,5R)-3,5-dihydroxy-7-(hydroxyamino)-7-oxoheptyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (S)-2-methylbutanoate 、 iron(III) perchlorate 在 HCl 作用下， 以 ethanol 、 methanol 、 aq. HClO₄ 为溶剂， 生成 [Fe(Me2C10H10(OC(O)CH(Me)Et)CH2CH2CH(OH)CH2CH(OH)CH2C(O)NHO)3]
  参考文献：
  名称：

  比色法测定纯形式和药物制剂中的辛伐他汀和洛伐他汀。

  摘要：

  描述了测定片剂中辛伐他汀和洛伐他汀的简单，准确和精确的比色法。该方法基于辛伐他汀或洛伐他汀与羟胺在碱性介质中反应，形成相应的异羟肟酸衍生物，该异羟肟酸衍生物在酸性介质中用三价铁离子处理后，生成高度着色的三价铁螯合物，在513nm处具有最大吸收。辛伐他汀和洛伐他汀的浓度范围分别为0.04-0.4mgml（-1），遵守比尔定律。根据比尔定律数据计算得出的辛伐他汀和洛伐他汀的摩尔吸收率值分别为1.15x10（3）和1.09x10（3）lmol（-1）cm（-1）。研究了该反应的最佳实验参数。评估了所描述程序的有效性。

  DOI：

  10.1016/j.saa.2010.04.015
• 作为产物：
  描述：

  洛伐他汀 在 羟胺 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 72.0h， 以98%的产率得到(1S,3R,7S,8S,8aR)-8-((3R,5R)-3,5-dihydroxy-7-(hydroxyamino)-7-oxoheptyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (S)-2-methylbutanoate
  参考文献：
  名称：

  [EN] NOVEL CLASS OF COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE
  [FR] NOUVELLE CLASSE DE COMPOSÉS DESTINÉS AU TRAITEMENT D'UNE MALADIE CARDIOVASCULAIRE

  摘要：

  本发明涉及医学领域，具体是心血管疾病的治疗和预防领域。

  公开号：

  WO2017137469A1

文献信息

• [EN] NOVEL CLASS OF COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE<br/>[FR] NOUVELLE CLASSE DE COMPOSÉS DESTINÉS AU TRAITEMENT D'UNE MALADIE CARDIOVASCULAIRE
  申请人：STICHTING KATHOLIEKE UNIV

  公开号：WO2017137469A1

  公开（公告）日：2017-08-17

  The present invention relates to the field of medicine, specifically the field of treatment and prevention of cardiovascular diseases.

  本发明涉及医学领域，具体是心血管疾病的治疗和预防领域。
• NOVEL CLASS OF COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE
  申请人：STICHTING KATHOLIEKE UNIVERSITEIT

  公开号：US20190038588A1

  公开（公告）日：2019-02-07

  The present invention relates to the field of medicine, specifically the field of treatment and prevention of cardiovascular diseases.
• Novel class of compounds for the treatment of cardiovascular disease.
  申请人：Stichting Katholieke Universiteit

  公开号：US20210169838A1

  公开（公告）日：2021-06-10

  The present invention relates to the field of medicine, specifically the field of treatment and prevention of cardiovascular diseases.
• [EN] C PRIME AGENTS FOR TREATING METABOLIC DISORDERS<br/>[FR] AGENTS C PRIME POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES
  申请人：[en]THE UNIVERSITY OF TOLEDO

  公开号：WO2022165395A1

  公开（公告）日：2022-08-04

  Stably consolidated compounds assembled from a statin and a metformin analog, and metabolically labile dual prodrugs assembled from the same, methods of making both, and methods of using them to treat metabolic diseases such as cancers are described.
• Design and Synthesis of Dual-Action Inhibitors Targeting Histone Deacetylases and 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase for Cancer Treatment
  作者：Jhih-Bin Chen、Ting-Rong Chern、Tzu-Tang Wei、Ching-Chow Chen、Jung-Hsin Lin、Jim-Min Fang

  DOI：10.1021/jm400179b

  日期：2013.5.9

  A series of dual-action compounds were designed to target histone deacetylase (HDAC) and 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) by having a hydroxamate group essential for chelation with the zinc ion in the active site of HDAC and the key structural elements of statin for binding with both proteins. In our study, the statin hydroxamic acids prepared by a fused strategy are most promising in cancer treatments. These compounds showed potent inhibitory activities against HDACs and HMGR with IC50 values in the nanomolar range. These compounds also effectively reduced the HMGR activity as well as promoted the acetylations of histone and tubulin in cancer cells, but were not toxic to normal cells.